We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Delivery Technique Hits Solid Tumors with Arsenic Trioxide

By LabMedica International staff writers
Posted on 26 Jul 2010
A new delivery mechanism has been developed that allows the classic chemotherapeutic agent arsenic trioxide to kill solid tumors effectively.

Conventional wisdom has been that arsenic trioxide, which works against some types of leukemia, cannot be used against solid tumors because of its extreme toxicity and rapid excretion from the body.

However, in a paper published in the July 2010 issue of the journal Clinical Cancer Research investigators at Northwestern University (Evanston, IL, USA) described a method for encapsulating arsenic trioxide inside nanoparticle-sized liposomal vesicles to form what they called "nanobins.” Efficacy of treatment with arsenic trioxide nanobins was evaluated in breast cancer-cell cultures and in a mouse model of human "triple-negative” breast cancer.

Results showed that while the nanobins were much less cytotoxic in vitro than free arsenic trioxide against the panel of human breast cancer-cell lines, they dramatically increased the therapeutic efficacy of arsenic trioxide in vivo in the mouse model of triple-negative breast cancer. More...
Reduced plasma clearance, enhanced tumor uptake, and induction of tumor cell apoptosis were observed following nanobin treatment. None of these effects was seen in animals treated with arsenic trioxide alone or with empty nanobins.

"Everyone said you cannot use arsenic for solid tumors,” said senior author Dr. Tom O'Halloran, professor of chemistry and biochemistry at Northwestern University. "That is because they did not deliver it the right way. This new technology delivered the drug directly to the tumor, maintained its stability, and shielded normal cells from the toxicity. That is huge. Once you fine-tune this, you could use what would otherwise be a lethal or highly toxic dose of the drug, because a good deal of it will be directly released in the tumor.”

Related Links:
Northwestern University




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.